ASCO2014 UPDATES

ASCO 2014 was more than just big headlines – press releases trickled in for the entire week afterwards, and while the major announcements hit the wires in real time, the smaller findings and stories had their time to shine, too. Here is a little more insight about the future of cancer research presented at the ASCO annual meeting at the beginning of June, and a few more abstracts which suggest change of our Oncology Practice.Trivandrum Oncology Clubn will be discussing practice changing abstracts presented in various diciplines of Clinical Oncology.

Programme 7.30pm-9pm Hotel SP Granddays

Moderators: Prof. M Krishnan Nair, Prof.PG Jayaprakash

Topic  Presentation of practice changing Asco 2014 abstracts

1.  Paediatric Oncology

Dr.Binitha ( RCC)

1. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.

2. The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) protocol AALL0433.

3. Subsequent neoplasms in the fifth and sixth decades of life in the Childhood Cancer Survivor Study cohort.

4. A neuroblastoma risk classification model for developing countries: A study from the International Neuroblastoma (NB) Risk Group (INRG) database

5. Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

2.Haemato-oncology

Shruthi Prem( RCC)

Topics

1.Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia  

(Abstract 7005)

2. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.

(Abstract 7014)

3. Idelalisib + Rituximab in Relapsed CLL: Phase III Study

(Abstract 7012.)

3.Head and Neck and Breast Oncology

Dr.Cessal kainackal ( RCC)

Doxorubicin + Cyclophosphamide  and Paclitaxel ± Bevacizumab in BC (E5103)

Meta-analysis of Adjuvant Trastuzumab in   HER2+ Breast Cancer

Phase III POEMS Trial: LHRH Analogue Treatment During Chemotherapy

OPTIMIZE-2 Study: Frequency of Continued Zoledronic Acid for Bone Mets

4.Uro-oncology

Rajeev KR (RCC)

chemo hormonal therapy vs androgen ablation: randomized trial for extensive disease prostate cancer(E3805)

 

5.GI Oncology

1.CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

2.Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial.

3.Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.

6.Surgical Oncology

Madhu Muralee (Surgical Oncology)